T. Ahmed

发表

Predicting sentinel node positivity in patients with melanoma: external validation of a risk‐prediction calculator (the Melanoma Institute Australia nomogram) using a large European population‐based patient cohort *

P. V. van Diest, R. Scolyer, J. Thompson, 2021, The British journal of dermatology.

Association between gene expression, clinical factors and survival in patients with breast cancer

T. Ahmed, 2018 .

Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor.

P. V. van Diest, R. Scolyer, J. Thompson, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites

K. Shannon, J. Wilmott, R. Scolyer, 2022, Journal for ImmunoTherapy of Cancer.

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

P. Ascierto, Douglas B. Johnson, G. Long, 2022, Journal for ImmunoTherapy of Cancer.

Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant to PD1 monotherapy.

P. Ascierto, C. Blank, G. Long, 2020 .

Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial.

R. Scolyer, L. Haydu, G. Long, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas.

P. V. van Diest, R. Scolyer, A. Witkamp, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy

J. Wilmott, R. Scolyer, G. Long, 2022, Journal for ImmunoTherapy of Cancer.

Effect of the SunSafe Student Ambassador Program on the attitudes, knowledge and behaviour of Australian high‐school students towards sun safety: a prospective study

Derek S. Bryan, K. Shannon, R. Scolyer, 2022, Clinical and experimental dermatology.

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

M. Weichenthal, K. Kähler, P. Ascierto, 2022, Journal for ImmunoTherapy of Cancer.

Histological regression in melanoma: impact on sentinel lymph node status and survival

K. Shannon, R. Scolyer, M. El Sharouni, 2021, Modern Pathology.

Clinical Models to Define Response and Survival With Anti–PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma

M. Weichenthal, J. Utikal, D. Schadendorf, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets

J. Wilmott, R. Scolyer, G. Long, 2021, Cancers.

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.

P. Ascierto, Douglas B. Johnson, C. Blank, 2021, The Lancet. Oncology.

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients

J. Wilmott, R. Scolyer, G. Long, 2019, Oncoimmunology.

External validation of a prognostic model to predict survival of patients with sentinel node‐negative melanoma

R. Scolyer, J. Thompson, G. Long, 2019, The British journal of surgery.

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab

R. Scolyer, G. Long, T. Ahmed, 2020, Journal for ImmunoTherapy of Cancer.

Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data.

P. V. van Diest, R. Scolyer, J. Thompson, 2020, The British journal of surgery.

Whole brain radiotherapy (WBRT) after local treatment of brain metastases in melanoma patients: Statistical Analysis Plan

R. Scolyer, L. Haydu, H. Dhillon, 2019, Trials.

Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply.

P. Ascierto, Douglas B. Johnson, G. Long, 2021, The Lancet. Oncology.

Primary dermal melanoma: clinical behaviour, prognosis and treatment.

K. Shannon, R. Scolyer, R. Karim, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial

T. Ahmed, S. Lo, A. Hong, 2023, Clinical and translational radiation oncology.

Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases

K. Shannon, R. Scolyer, T. Ahmed, 2022, Annals of Surgical Oncology.

In vivo reflectance confocal microscopy can detect the invasive component of lentigo maligna melanoma: Prospective analysis and case–control study

C. Sinz, R. Scolyer, P. Guitera, 2023, Journal of the European Academy of Dermatology and Venereology : JEADV.

Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.

Douglas B. Johnson, C. Blank, G. Long, 2021 .

Abstract 975: Liver metastases (mets) induce systemic immunosuppression and immunotherapy resistance in metastatic melanoma

J. Wilmott, R. Scolyer, G. Long, 2019, Tumor Biology.